Fluidigm reported total revenues of $30.7 million, within its preannouncement range and ahead of analysts' consensus estimate.
The company attributed the growth in quarterly revenue to sales of its existing products and early interest in its new single-cell genomics system.
The South San Francisco-based genomics tools company reported $28.6 million in total revenues compared to $29.6 million in the year-ago period.
The firm expects to raise net proceeds of $13.6 million, which it will use to advance development and commercialization of its single-cell genomics products.
The company launched the BD FACSseq flow cytometer and BD Precise Assays for high-throughput single-cell gene-expression analysis studies at the ASHG annual meeting.
The company reported preliminary Q3 revenue growth of between 52 percent and 68 percent, and raised its revenue guidance for full-year 2015.
The single-cell genomics center at the Monash Health Translation Precinct near Melbourne will be the first of its kind in Australia.
The center expands the collaboration between the two organizations at the Jackson Laboratory for Genomic Medicine.
BD plans to pair Cellular Research's highly multiplexed gene expression technology with its flow cytometry platforms.
The company also significantly reduced its full-year 2015 revenue guidance, and noted that it has initiated organizational changes to address underlying issues.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.